Evaluation of risk factors associated with clinical improvement and survival of horses with equine protozoal myeloencephalitis.
OBJECTIVE
To investigate risk factors for use in predicting clinical improvement and survival of horses with equine protozoal myeloencephalitis (EPM).


METHODS
Longitudinal epidemiologic study.


METHODS
251 horses with EPM.


METHODS
Between 1992 and 1995, 251 horses with EPM were admitted to our facility. A diagnosis of EPM was made on the basis of neurologic abnormalities and detection of antibody to Sarcocystis neurona or S neurona DNA in CSF. Data were obtained from hospital records and through telephone follow-up interviews. Factors associated with clinical improvement and survival were analyzed, using multivariable logistic regression.


RESULTS
The likelihood of clinical improvement after diagnosis of EPM was lower in horses used for breeding and pleasure activities. Treatment for EPM increased the probability that a horse would have clinical improvement. The likelihood of survival among horses with EPM was lower among horses with more severe clinical signs and higher among horses that improved after EPM was diagnosed.


CONCLUSIONS
Treatment of horses with EPM is indicated in most situations; however, severity of clinical signs should be taken into consideration when making treatment decisions. Response to treatment is an important indicator of survival.
Saville
W J
WJ
Department of Veterinary Preventive Medicine, College of Veterinary Medicine, The Ohio State University, Columbus 43210, USA.
Morley
P S
PS
Reed
S M
SM
Granstrom
D E
DE
Kohn
C W
CW
Hinchcliff
K W
KW
Wittum
T E
TE
D000818:Animals; D020808:Central Nervous System Protozoal Infections / Q000401:mortality / Q000628:therapy / Q000662:veterinary*; D004679:Encephalomyelitis / Q000401:mortality / Q000628:therapy / Q000662:veterinary*; D005260:Female; D006734:Horse Diseases / Q000401:mortality* / Q000628:therapy; D006736:Horses; D008137:Longitudinal Studies; D008297:Male; D011379:Prognosis; D012189:Retrospective Studies; D012307:Risk Factors; D012523:Sarcocystosis / Q000401:mortality / Q000628:therapy / Q000662:veterinary*; D016019:Survival Analysis